

**1) Personal Data**

Susie Quong Lew  
Citizenship: USA

**2) Education**

Undergraduate:

Sept 1972 - June 1976

B.S. Chemistry, Brooklyn College  
Brooklyn, New York

Medical:

Sept 1975 - May 1979

M.D., SUNY Downstate Medical Center  
450 Clarkson Avenue  
Brooklyn, New York 11203  
(7-year BA-MD program)

Post Graduate Training:

July 1979 - June 1982

Internal Medicine, PGY 1-3  
Brookdale Medical Center  
Brookdale Plaza  
Brooklyn, New York 11212

July 1982 - June 1985

Nephrology Fellowship  
Mount Sinai Medical Center  
1 Gustave Levy Place  
New York, New York 10029

### 3) Employment

#### Academic Appointments:

July 1985 – June 1994 Assistant Professor, George Washington University  
July 1994 – June 1999 Associate Professor, George Washington University  
July 1999 – present Professor  
Division of Renal Diseases and Hypertension  
Department of Medicine  
George Washington University Medical Center  
2300 Eye Street, NW  
Washington, DC 20037

#### Appointments:

July 1985 - present Attending Physician  
Division of Nephrology, Department of Medicine  
George Washington University Medical Center  
901 23<sup>rd</sup> Street, NW  
900 23<sup>rd</sup> Street, NW (new hospital 2002)  
Washington, DC 20037

July 1985 - present Attending Physician  
Division of Nephrology, Department of Medicine  
Medical Faculty Associates (1999)  
George Washington University Medical Center  
2150 Pennsylvania Avenue, NW  
Washington, DC 20037

July 1985 - present Medical Director, Peritoneal Dialysis Unit  
George Washington University Medical Center-  
Gambro Healthcare / DaVita (2005)

July 1991 - 2013 Medical Director, Hemodialysis  
George Washington University Medical Center-  
Gambro Healthcare / DaVita (2005)  
Acute Hemodialysis Unit

July 1991 – 2002  
July 2005 – 2013 Medical Director, Hemodialysis  
George Washington University Medical Center-  
Gambro Healthcare/DaVita (2005)

July 2001 – 2004 Chronic Hemodialysis Unit  
Administrative Medical Director  
Gambro Healthcare

July 2008 – 2009 Medical Director, DaVita Village Health

#### **4) Professional Registrations, Licenses, Certifications**

##### Medical Licensure:

1980 - 1985 New York State  
1985 - present District of Columbia  
1994 - 2004 Maryland  
1995 - present Virginia

##### Certifications:

1983 American Board of Internal Medicine,  
Medicine,  
1986 American Board of Internal Medicine,  
Nephrology,

#### **5) Societies and Honors**

##### Membership in Professional Associations:

1980 – present American College of Physicians  
1990 Fellow American College of Physicians  
1986 – 2017 International Society of Nephrology  
1986 - present American Society of Nephrology  
2004 Fellow American Society of Nephrology  
2019-2022 ASN Quality Committee  
2020 ASN COVID-19 Home Dialysis Subcommittee  
1987 – present National Kidney Foundation  
1992 - 1997 Professional Advisory Board  
1998 - 2003 Research Committee  
2012 Fellow of the National Kidney Foundation  
1987 - 1996 Chinese Medical & Health Association  
1989 - 1991 American Federation for Clinical Research  
1989 - present Society of Chinese Bioscientists in America  
1991 - 1995 American Society for Artificial Internal Organs  
1992 - 1993 International Society for Peritoneal Dialysis  
1992 American Medical Association  
1997 International Society of Peritoneoscopists  
2020 International Society of Peritoneal Dialysis

##### Honors

2004, 2005, 2008, 2010, 2012, 2013, 2014, 2015, 2016, 2017, 2019, 2020  
Washingtonian, Top Doctors  
2011, 2012, 2013, 2014, 2015, 2016  
Washington Post, Super Doctors  
2012, 2013, 2014, 2015, 2016  
US News and World Report Top Doctors  
June 2013 National Kidney Foundation Volunteer Service Award

**6) Administrative Duties & University Activities at George Washington University Medical Center**

Departmental

1988 – 2006: Director of the Renal Division Fellowship Program  
1991 Medical Records Committee - MFA  
1997 – present Department of Medicine, Committee on Appointments, Promotion, and Tenure – member  
  
1998 – 2006: Associate Director, Division of Renal Diseases and Hypertension  
2001: Acting Division Director, Renal Diseases and Hypertension  
2001- present: Chief of Clinical Outpatient Services, Renal Diseases and Hypertension  
  
2006 - 2009 Interim Director, Division of Renal Diseases and Hypertension  
2017 - Department of Medicine, Committee on Appointments, Promotion, and Tenure - Chair  
  
2018 - 2020 Board Member, GW-MFA Accountable Care Organization  
2018 Member, Search Committee for Division Director of GIM

University

2012 Chair, Expedited Search for Dermatology Department Chair

**7) Educational Achievements:**

a) Courses Taught:

1985- present ICM - renal

**8) Consultant Appointments**

Consult for:

1992 – 1997 American Board of Internal Medicine  
1995 - 2003 Connectance  
1996 - present Food and Drug Administration – Devices  
2007, 2008, 2009 Amgen Advisory Board  
2007 Ortho Biotech Products Advisor consulting  
2009 – 2014 Gambro Renal Products, Inc.  
2014 - 2017 US Food and Drug Administration: Gastroenterology and Urology Devices Panel of FDA’s Medical Devices Advisory Committee  
May 6, 2016 Rogosin Institute: Nutrition and Renal Disease: What can we do to improve outcomes in individuals living with chronic kidney disease (CKD) and end stage renal disease (ESRD)  
March 2017 Baxter Renal Nephrology Advisory Board  
August 2018 -2022 Data Safety Monitoring Board: NIH Kidney Precision Medicine Project

August 2, 2018 CMS/CMMI: Nephrologist roundtable on home dialysis with Deputy Administrator and CMMI Director Adam Boehler and CMMI Chief Medical Officer Anand Shah.

Review for:

1990 – 1992: Institute of Biomedical Sciences, Academia Sinica, Taiwan  
1992 – present: Kidney International , Published by Williams & Wilkins  
1994 – present: Journal of the American Society of Nephrology  
Published by Williams & Wilkins  
1996 – present: American Journal of Kidney Diseases,  
Published by W.B. Saunders Company  
1996: American Society of Nephrology,  
Annual Meeting Program Committee Abstract Review,  
Hemodialysis Complications  
1997 – 2006: National Institute of Health,  
Multidisciplinary Sciences Special Emphasis Panel, Bethesda, MD  
1998: American Society of Nephrology,  
Annual Meeting Program Committee Abstract Review:  
Complications of Peritoneal Dialysis  
2000 – 2005: National Institute of Health, DK-D Committee, Bethesda, MD  
2001 – present: Nephrology Dialysis Transplantation,  
Published by Oxford University Press  
2000, 2002, 2004, 2006, 2007, 2008 (regular member) – 2012, 2013 ad hoc  
National Institute on Aging Special Emphasis Panel,  
Bethesda, MD  
2003 Quality Council, Gambro Healthcare  
2004, 2006, 2011 National Institute on Aging Special Emphasis Panel, Pepper Center  
Bethesda, MD  
2006: National Institute on Aging Special Emphasis Panel, Inflammation  
and Aging, Bethesda, MD  
2006 – present: Peritoneal Dialysis International  
Published by Multimed Inc, Milton, Canada  
2008 – present: Therapeutic Apheresis and Dialysis  
Blackwell Publishing  
2008 – 2015: National Institute on Aging: NIA-C  
Bethesda, MD  
2009 – present: Clinical JASN  
Published by American Society of Nephrology  
2010 – present Clinical Nephrology  
Published by Dustri-Verlag  
2010 Medical Center Facilitating Fund  
George Washington University  
2011 International Medical Case Reports Journal  
Published by Dove Medical Press  
2013 Journal of Diabetes and Endocrinology  
Academic Journals

2013 – present	British Medical Journal Case Reports
2014 -- present	Clinical Kidney Journal
	Official Journal of European Renal Association – European Dialysis and Transplant Association. Published by Oxford Journals
2014 –present	Biomedical Journals
2014 – present	Hemodialysis International
	Published by Wiley
2015 -- present	Saudi Medical Journal
2018 -- present	Expert Review of Medical Devices
	Published by Taylor and Francis
2018	American Journal of Nephrology
	Published by Karger Publishers
2019, 2020	ASN KidneyX Reviewer
2019--	National Institute of Health, Clinical Aging Study Section (NIA-C)
	Bethesda, MD
2019 July 31	National Institute on Aging Special Emphasis Panel (NIA-ZAG1 ZIJ-7 (O1), Member Conflict SEP)
2020 September 17	Innovative Medical Devices Initiative: “Technology for Sustainable Healthcare Demonstration projects” programme from The Netherlands Organisation for Health Research (ZonMw), Netherlands Organisation for Scientific Research (NOW) and Health Holland

### **9) Grants Awarded or Pending**

- BRSg-NIH2-S07-RR05359-24#11-86  
The early renal hemodynamics in diabetes mellitus.  
Role: Principal investigator  
Sponsor: NIH  
Project Period: 1/1/86 to 12/31/86
- BRSg-NIH2-S07-RR05359-27  
The significance of proteinuria: GFR or renal disease?  
Role: Co-Principal investigator  
Sponsor: NIH  
Project Period: 1/1/89 to 12/31/89
- FDA guidance for dialyzer reuse labeling: Equivalence of the safety and effectiveness of the Asahi AM-90U-SD series dialyzers.  
Role: Principal investigator.  
Sponsor: Asahi Medical Co., Ltd., Tokyo, Japan  
Project Period: 1996
- AM-SD dialyzer in-vitro testing protocol.  
Role: Principal investigator.  
Sponsor: Asahi Medical Co., Ltd., Tokyo, Japan  
1996
- Safety and efficacy of levocarnitine supplementation in end-stage renal disease patients undergoing maintenance hemodialysis: A multi-center, dose ranging study, Protocol No. ST-96001.  
Role: Site principal investigator (multi-center)  
Sponsor: Sigma Tau Corporation, Gaithersburg, MD  
Project Period: 1997 – 1998
- AM BIO WET dialyzer in-vitro performance testing protocol.  
Role: Principal investigator.  
Sponsor: Asahi Medical Co., Ltd., Tokyo, Japan  
Project Period: 1998
- Clinical investigation of AM-BIO series dialyzer.  
Role: Principal investigator.  
Sponsor: Asahi Medical Co., Ltd., Tokyo, Japan  
Project Period: 1998
- Clinical measurement of complement activation in currently marketed hemodialyzers.  
Role: Principal investigator.  
Sponsor: Asahi Medical Co., Ltd., Tokyo, Japan  
Project Period: 1998

- An open-label, randomized study of novel erythropoiesis stimulating protein (NESP) and recombinant human erythropoietin (r-HuEPO) for the treatment of anemia in patients with end-stage renal disease (ESRD).

Role: Site principal investigator (multi-center)

Sponsor: Amgen Inc., Thousand Oaks, CA

Project Period: 1999-2000

- NIH R01-DK45578

Title: Depression and survival in hemodialysis patients.

Role: Principal investigator

Sponsor: NIH

Project Period: 1999-2000

- Clinical investigation of the APS series dialyzers

Role: Principal investigator

Sponsor: Asahi Medical Company, Ltd., Tokyo, Japan

Project Period: 1999-2000

- APS dialyzer in-vitro performance testing protocol.

Role: Principal investigator

Sponsor: Asahi Medical Company, Ltd., Tokyo, Japan

Project Period: 1999-2000

- Crossover, randomized, blinded, prospective, multicenter clinical evaluation of the rate of adverse effects to Ferrlecit in hemodialysis patients compared to placebo and historical controls

Role: Site principal investigator (multi-center)

Sponsor: R&D Laboratories, Inc.

Project Period: 1999-2000

- FD-R-001513-01

Title: Comparison of IV cyclophosphamide to mycophenolate mofetil for induction therapy of active class IV nephritis in systemic lupus erythematosus (IND#55,262)

Role: Site co-principal investigator (multi-center)

Sponsor: FDA

Project Period: 2000-2002

- Open-label, prospective, multicenter study to evaluate the rate of adverse events and their relationship to concomitant administration of angiotensin converting enzyme inhibitor therapy following repeated administration of Ferrlecit (sodium ferric gluconate complex in sucrose injection) in hemodialysis patients receiving erythropoietin.

Role: Site principal investigator (multi-center)

Sponsor: R&D Laboratories, Inc.

Project Period: 1999-2000



- NESP 990788: A study evaluating the initiation and titration of fixed doses of novel erythropoiesis stimulating protein (NESP) therapy in subjects with chronic renal insufficiency

Role: Site principal investigator (multi-center)

Sponsor: Amgen, Inc

Project Period: 2000-2001

- The effect of Viagra (sildenafil) in dialysis patients

Role: Principal investigator

Sponsor: Pfizer, Inc.

Project Period: 2001-2002

- NESP 2001-0212: Study to assess the efficiency of darbepoetin alfa (NESP) administered once every four weeks in subjects with chronic renal insufficiency (CRI)

Role: Site principal investigator (multi-center)

Sponsor: Amgen, Inc

Project Period: 2002-2003

- Clinical evaluation of the Polyflux 10L hemodialyzer

Role: Principal investigator

Sponsor: Gambro

Project Period: 2002-2003

- A randomized controlled trial of the benefits of oral essential amino acids in recently hospitalized hemodialysis patients. CT00-AMI-003

Role: Site principal investigator (multi-center)

Sponsor: Gambro / Recip AB

Project Period: 2002-2003

- SBIR R41 DK064500

Title: Feasibility study of a double fiber bundle dialyzer

Role: Consultant:

Principal Investigator: Gary Mishkin

Sponsor: MiriMedical LLC

Project Period: 2005-2007

- 5R42DK064500-04

Title: Safety and efficacy evaluation of the double fiber bundle dialyzer

Role: Consultant

Principal Investigator: Gary Mishkin

Sponsor: MiriMedical LLC

Project Period: 2009-2014

- NESP 980117A randomized, double-blind study comparing Aranesp (darbepoetin alfa) and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African-American subjects with chronic renal failure (CRF) receiving hemodialysis.

Role: Site principal investigator (multi-center)

Sponsor: Amgen

Project Period: 2003-2004

- NESP 2001-0184 Trial to reduce cardiovascular events with Aranesp therapy (TREAT)

Role: Site principal investigator (multi-center)

Sponsor: Amgen, Inc

Project Period: 2005-2006

- A Phase III, open-label study of the safety and efficacy of ferumoxytol (compared with oral iron) as an iron replacement therapy in chronic kidney disease patients not on dialysis. Protocols 62,745-6 and 62,745-7

Role: Site principal investigator (multi-center)

Sponsor: Advanced Magnetics, Inc

Project Period: 2005-2006

- A Phase III, open-label study of the safety and efficacy of two parental dose regimens of ferumoxytol, compared with oral iron, as an iron replacement therapy in chronic kidney disease patients on hemodialysis who are receiving stable supplemental EPO therapy. Protocols 62,745-5

Role: Site principal investigator (multi-center)

Sponsor: Advanced Magnetics, Inc

Project Period: 2005-2006

- Epoetin alfa 20040259: A randomized, open-label study to assess the safety of epoetin alfa manufactured by deep tank technology and epoetin alfa manufactured by roller bottle technology in subjects with chronic kidney disease not on dialysis

Role: Site principal investigator (multi-center)

Sponsor: Amgen, Inc

Project Period: 2005-2007

- SBIR 2R44HL074524-02

Title: Measuring intra/extracellular volume and hemodynamics

Role: Site co-investigator

Sponsor: LDM Associates

Project Period: 2006-2008

- A Phase III, randomized, double-blind, placebo-controlled study of AST-120 for prevention of chronic kidney disease progression in patients with moderate to severe chronic kidney disease.

Role: Site principal investigator (multi-center)

Sponsor: Mitsubishi Tanabe Pharma Corporation/KUREHA CORPORATION

Project Period: 2008-2011

- AFX01-11: A Phase 3, randomized, active-controlled, open-label, multi-center study of the safety and efficacy of AF37702 injection for the correction of anemia in patients with chronic renal failure (CRF) not on dialysis and not on erythropoiesis stimulating (ESA) treatment.

Role: Site principal investigator (multi-center)

Sponsor: Affymax, Inc

Project Period: 2008-2010

- CK-LX3405: The LIBRA Study: Multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral lixivaptan capsules in subjects with euvolemic hyponatremia

Role: Site principal investigator (multi-center)

Sponsor: Cardiokine

Project Period: 2009

- Whole blood platelet aggregation and release reaction testing in uremic patients

Role: Co-investigator: Louis DePalma, MD

Project Period: 2009-2011

- 402-C-0903: Bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (BEACON)

Role: Site principal investigator (multi-center)

Sponsor: Reata Pharmaceuticals, Inc

Project Period: 2011- 2012

- A randomized, placebo-controlled, parallel-group, double-blind study of H.P. Acthar Gel (Acthar) in treatment-resistant subjects with persistent proteinuria and nephritic syndrome due to idiopathic membranous nephropathy (iMN)

Role: Site principal investigator (multi-center)

Sponsor: Questcor Pharmaceuticals, Inc

Project Period: 2011

- 156-10-291: A multi-center, longitudinal, observational study of patients with autosomal dominant polycystic kidney disease (ADPKD) to establish the rate, characteristics, and determinants of disease progression.

Role: Sub-investigator

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc

Project Period: 2011

- 20110226: START-CKD strategies using darbepoetin alfa to avoid transfusions in chronic kidney disease

Role: Site principal investigator (multi-center)

Sponsor: Amgen, Inc

Project Period: 2012

- Using telemedicine in peritoneal dialysis to improve patient adherence and outcomes while reducing overall cost of care

Role: Principal investigator

Sponsor: CMS

Project Period: July 2012 to June 2015

- The Dialysis Outcomes & Practice Patterns Study (DOPPS)

Role: Principal investigator (multi-center)

Sponsor: Arbor Research Collaborative for Health

Project Period: 2012-2015

- A Double-Blind, Placebo-Controlled, Randomized, Two-stage, Parallel-Group, Adaptive Design Phase 2a Study to Evaluate the Effects of BMS-813160 in Subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease (DKD) Who Have Residual Macroalbuminuria Despite Treatment with an Inhibitor of the Renin-Angiotensin System

Role: Principal investigator (multi-center)

Sponsor: Bristol-Myers Squibb Company

Project Period: 2013

- The Dialysis Outcomes & Practice Patterns Study (DOPPS)

Role: Principal investigator (multi-center)

Sponsor: Arbor Research Collaborative for Health

Project Period: 2015-2018

- Improving Specialty Care via Telemedicine

Proving specialty care for underserved patients in Washington, D.C.'s Ward 7 & 8 through creation of a telemedicine clinic at Unity Health Care's Anacostia location.

Role: Co-Principal Investigator

Sponsor: CareFirst Foundation

Project Period: 2016-2019, extended to March 31, 2020

## 10) Publications

### a) Papers in Refereed Journals

1. Bosch JP, Lew S, Glabman S, Lauer A. Renal hemodynamic changes in man: Response to protein loading in the normal and diseased kidney. *Am J Med* 1986;81:809-815.
2. Lew SQ, Bosch JP. Effect of diet on creatinine clearance and excretion in young and elderly, healthy subjects and in patients with renal disease. *J Am Soc Nephrol* 1991; 2(4):856-865.
3. Blank MJ, Lew SQ. Hypoventilation in a dialysis patient with severe metabolic alkalosis. *Blood Purification* 1991;9:109-113.
4. Lew SQ, Watson JA. Urea and creatinine generation and removal in a pregnant patient receiving peritoneal dialysis. *Adv Perit Dial* 1992; pp 131-135.
5. Lew SQ. When to use continuous therapy: Continuous arteriovenous hemofiltration (CAVH) or continuous venovenous hemofiltration (CVVH). *Int J Artif Organs* 1992; 15(11): 633-6.
6. Pearson P, Lew S, Abramson F, Bosch J. Measurement of kinetic parameters for urea in a two-compartment model. *J Am Soc Nephrol* 1994;4:1869-1873.
7. Ronco C, Conz P, Agostini F, Bosch JP, Lew SQ, La Greca G. The concept of adequacy in peritoneal dialysis. *Perit Dial Int* 1994; 14:S93-98.
8. Bosch JP, Watson J, Lew SQ. Nutritional targets in peritoneal dialysis and markers of adequacy. *Perit Dial Int* 1994; 14:S105-109.
9. Ronco C, Bosch JP, Lew SQ, Feriani M, Chiaramonte S, Conz P, Brendolan A, La Greca G. Adequacy of continuous ambulatory peritoneal dialysis: Comparison with other dialysis techniques. *Kidney Int* 1994; 46 (Suppl 48): S18-24.
10. Pham PT, Miller JM, Dimitrion G, Lew SQ. Clotting of hemoaccess for hemodialysis in an end stage renal disease patient by heparin. *Am J Kidney Dis* 1995; 25(4):642-647.
11. Lew SQ, Habwe VQ, Earley S, Watson J, Bosch JP. Effect of hematocrit on D/P ratio in peritoneal dialysis. *Perit Dial Int* 1995; 15(6):8-9 .
12. Kimmel PL, Lew SQ, Umana WO, Li PP, Straw J. Pharmacokinetics of zidovudine in HIV infected patients with end stage renal disease. *Blood Purif* 1995;13:340-346.
13. Kimmel PL, Phillips TM, Lew SQ, Langman CB. Zinc modulates mononuclear cellular calcitriol metabolism in peritoneal dialysis patients. *Kidney Int* 1996; 49:1407-1412.
14. Osman BA, Lew SQ. Vancomycin removal by plasmapheresis. *Pharm Tox* 1997;81:245-246.
15. Velasquez MT, Lew SQ, von Albertini B, Mishkin GJ, Bosch JP. Control of hypertension is better during hemodialysis than during continuous ambulatory peritoneal dialysis in ESRD patients. *Clin Neph* 1997;48(6):341-345.
16. Pham PT, Lew SQ, Balow JE. Sickle cell nephropathy during the postpartum period in a patient with systemic lupus erythematosus. *Am J Kidney Dis* 1997;30(6):879-883.
17. Mishkin GJ, Lew SQ, Bosch JP. Assessment of PD treatment delivered by I<sup>125</sup> - Iothalamate plasma disappearance. *Clin Neph* 1998;49:173-179.

18. Velasquez MT, von Albertini B, Lew SQ, Mishkin GJ, Bosch JP. Equal levels of blood pressure control in ESRD patients receiving high-efficiency hemodialysis and conventional hemodialysis. *Am J Kidney Dis* 1998;31:1-8.
19. Castillo AA, Lew SQ, Smith A, Whyte R, Bosch JP. Vaginal candidiasis: A source for fungal peritonitis in peritoneal dialysis? *Perit Dial Int* 1998;18(3):338-339.
20. Gholami P, Lew SQ. Raw shellfish consumption among renal disease patients: A risk factor for severe *Vibrio vulnificus* infection. *Am J Prev Med* 1998;15(3):243-245.
21. Gao H, Lew SQ, Bosch JP. The effects of increasing exchange volume and frequency on peritoneal dialysis adequacy. *Clin Neph* 1998;50(6):375-380.
22. Castillo AA, Lew SQ, Smith AM, Whyte RL, Bosch JP. Peritoneal dialysis-associated peritonitis caused by *Propionibacteria* sp. *Am J Kidney Dis* 1999;33(2):E6.
23. Gao H, Lew SQ, Bosch JP. Biochemical parameters, nutritional status and efficiency of dialysis in CAPD and CCPD patients. *Am J Nephrol* 1999;19:7-12.
24. Gao H, Lew SQ, Mishkin GJ, Bosch JP. The impact of residual renal function and total body water volume on achieving adequate dialysis in CAPD. *J Nephrol* 1999;12:184-189.
25. Vera G, Lew SQ. *Mycobacterium fortuitum* peritonitis in two patients receiving continuous ambulatory peritoneal dialysis. *Am J Nephrol* 1999;19(5):586-589.
26. Varela P, Smith AM, Whyte RL, Bosch JP, Lew SQ. Outcome of an opportunistic infection after polymicrobial peritonitis in an HIV positive patient on peritoneal dialysis. *Am J Nephrol* 1999;19:682-685.
27. Pham PTT, Pham PCT, Wilkinson AH, Lew SQ. Renal abnormalities in sickle cell disease. *Kidney Int* 2000;57:1-8.
28. Gao H, Lew SQ, Bosch JP. Moderate metabolic acidosis and its effects on serum parameters in hemodialysis patients. *Nephron* 2000;86:135-138.
29. Varela MP, Kimmel PL, Phillips TM, Mishkin GJ, Lew SQ, Bosch JP. Biocompatibility of hemodialysis membranes: Interrelations between plasma complement and cytokine levels. *Blood Purif* 2001;19:370-379.
30. Anwar N, Chawla LS, Lew SQ. Emphysematous pyelitis presenting as an acute abdomen in an ESRD patient treated with peritoneal dialysis. *Am J Kidney Dis* 2002;40:E13.
31. Castillo AA, Lew SQ, Smith AM, Whyte RL, Bosch JP. Discrepancies between adequacy goals in peritoneal dialysis: Role of gender. *Am J Kidney Dis* 2002;40(6):1301-1305.
32. Johnson A, Mishkin G, Lew SQ, Abramson F, Lecchi P. In vitro performance of hemodialysis membranes following repeated processing. *Am J Kidney Dis* 2003;42(3):561-566.
33. Eschelbacher D, Chawla LS, Lew SQ. Correction of respiratory acidosis by continuous renal replacement therapy. *J Applied Research* 2004;4(2):228-233.
34. Narayana VM, Lew SQ, Kimmel PL. Persistent hyponatremia ameliorated by discontinuation of hypertonic saline administration. *J Applied Research* 2004;4(2):261-265.
35. Lew SQ, Saez J, Whyte R, Stephenson Y. Peritoneal dialysis-associated peritonitis caused by *Staphylococcus auricularis*. *Perit Dial Int* 2004;24(2):195-196.

36. Lew SQ, Gruia A. Pseudomonas putida causing peritoneal dialysis associated peritonitis. *Perit Dial Int* 2005;25(5):503.
37. Bosch JP, Lew SQ, Barlee V, Mishkin GJ, von Albertini B. Clinical use of high-efficiency hemodialysis treatments: Long-term assessment. *Hemodial Int* 2006;10:73-81.
38. Lew SQ. Persistent hemoperitoneum in a pregnant patient receiving peritoneal dialysis. *Perit Dial Int* 2006; 26(1): 108-109.
39. Lew SQ. Hemoperitoneum: Bloody peritoneal dialysate in ESRD patients receiving peritoneal dialysis. *Perit Dial Int* 2007; 27(3): 226-233.
40. Lew SQ, Ing TS. Vascular access: Past, present, and future. *Int J Artif Organs* 2008; 31(5):382-385.
41. Lew, SQ. Amphotericin B removal by plasma exchange. *J Clin Pharm Ther* 2009;34:115-117.
42. Lew, SQ. Hydrothorax: Pleural effusion associated with peritoneal dialysis. *Perit Dial Int* 2010; 30: 13-18.
43. Lew SQ, Gruia A, Hakki F. Adult peritoneal dialysis patient with tenckhoff and percutaneous endoscopic gastrostomy catheter. *Perit Dial Int* 2011; 31: 360-36.
44. Siddiqui AC, Lew SQ, Sarin S, Venbrux AC. Emergency endovascular stenting of the right iliac artery in a patient with secondary haemorrhage following transplant nephrectomy. *BMJ Case Reports* 2012; June 8 .
45. Lew SQ, Gruia A. Ofloxacin solution for persistent PD exit site and tunnel infections. *Perit Dial Int* 2013; 33: 101-102 2012.
46. Montgomery LD, Gerth WA, Montgomery RW, Lew SQ, Klein MM, Stewart JM, Velasquez MT. Monitoring intracellular, interstitial, and intravascular volume changes during fluid management procedures. *Med Biol Eng Comput* 2013;51(10):1167-75.
47. Shoji J, Lew S. The use of rituximab and bendamustine in treating chronic lymphocytic leukemia (CLL) in end-stage renal disease (ESRD). *BMJ Case Reports* 2013 May 2; 2013.
48. Afshar M, Nobakht E, Lew S. Chryseobacterium indologenes peritonitis in peritoneal dialysis. *BMJ Case Reports* 2013 May 24; 2013.
49. Zeck J, Schalheim J, Lew SQ, DePalma L. Whole blood platelet aggregation and release reaction testing in uremic patients. *BioMed Res Int* 2013;2013:486290
50. Iheagwara OS, Ing TS, Kjellstrand CM, Lew SQ. Phosphorus, Phosphorous and Phosphates. *Hemodial Int* 2013; 17:479-482.
51. Lew SQ, Sikka N. Are patients prepared to use telemedicine in home peritoneal dialysis programs? *Perit Dial Int* 2013; 33: 714-715
52. Solano A, Lew SQ, Ing TS: Dent-Wrong disease and other rare causes of the Fanconi syndrome. *Clin Kidney J* 2014;7:344-347.
53. Lew SQ, Robinson JK 3<sup>rd</sup>. A conservative approach to peritoneal dialysis-associated rectocele. *Perit Dial Int* 2014; 34(6):655-657.
54. Lew SQ, Nguyen BN, Ing TS. Hemodialysis vascular access construction in the upper extremity: A review. *J Vasc Access* 2014;16:87-92.
55. Shokri T, Lew SQ, Sadeghi N. Pedicled parathyroid gland autotransposition in secondary and tertiary hyperparathyroidism. *Laryngoscope* 2015;125:894-897.

56. Lew SQ, Nguyen BN, Ing TS. Unusual sites for hemodialysis vascular access construction and catheter placement: A review. *Int J Artif Organs* 2015;38(6):293-303.
57. Lew SQ, Chernofsky MR. Uninterrupted peritoneal dialysis after robotic-assisted total laparoscopic hysterectomy. *Perit Dial Int* 2016;36(3):349-350.
58. Hynes M, Nicolas N, Lew S. Emerging concepts: the dietary treatment of chronic kidney disease. *J Kidney Care* 2017;2(3):134-143.
59. Montgomery LD, Montgomery RW, Gerth WA, Lew SQ, Klein MD, Stewart JM, Medow MS, Velasquez MT. Bioimpedance monitoring of cellular hydration during hemodialysis therapy. *Hemodial Int* 2017;21:575-584.
60. Magnus M, Sikka N, Cherian T, Lew SQ. Satisfaction and improvements in peritoneal dialysis outcomes associated with telehealth. *Appl Clin Inform* 2017;8(1):214-225.
61. Lew SQ, Kohn OF, Cheng YL, Kjellstrand CM, Ing TS. Three-stream, bicarbonate-based hemodialysis solution delivery system revisited: with an emphasis on some aspects of acid-base principles. *Artif Organs* 2017;41(6):509-518.
62. Lew SQ, Sikka N, Thompson C, Cherian T, Magnus M. Adoption of telehealth: Remote biometric monitoring among peritoneal dialysis patients in the United States. *Perit Dial Int* 2017;37(5):576-578.
63. Rosner MH, Lew SQ, Conway P, Ehrlich J, Jarrin R, Patel UD, Rheuban K, Robey RB, Sikka N, Wallace E, Brophy P, Sloand J. Perspectives from the Kidney Health Initiative on advancing technologies to facilitate remote monitoring of patient self-care in RRT. *Clin J Am Soc Nephrol* 2017;12:1900-1909.
64. Montgomery LD, Montgomery RW, Gerth WA, Loughry M, Lew SQ, Velasquez MT. A system to monitor segmental intracellular, interstitial, and intravascular volume and circulatory changes during acute hemodialysis. *J Electr Bioimp* 2017;8:40-53.
65. Lew SQ. Peritoneal dialysis immediately after abdominal surgery. *Perit Dial Int* 2018;38:5-8.
66. Lew SQ, Sikka N. Telehealth and peritoneal dialysis in the US: outcomes in practice. *J Kidney Care* 2018;3(3):156-160.
67. Emami S, Lew SQ. *Candida glabrata* PD-associated peritonitis: A case report. *Perit Dial Int* 2018;38(5): 391-392.
68. Lew SQ, Sikka N, Thompson C, Magnus M. Impact of remote biometric monitoring on cost and hospitalization outcomes in peritoneal dialysis. *J Telemed Telecare* 2019;25(10):581-586.
69. Lew SQ, Sikka N. Operationalizing telehealth for home dialysis patients in the United States. *Am J Kidney Dis*. 2019;74:95-100.
70. Montgomery LD, Montgomery RW, Gerth WA, Lew SQ, Velasquez MT, Stewart JM, Medow MS, Klein MM. Monitoring intracellular (Vc), interstitial (Vi) and intravascular (Vb) volume changes during dialysis (HD) in a chronic unit (CU) compared to an acute unit (AU) setting. *J Nephrol Kidney Dis*. 2019;3(1): 1019
71. Paul R, Hynes M, Lew SQ. Nutrition in kidney transplant recipients to prevent downstream health issues. *J Kidney Care* 2019; 4(5):252-260.
72. Lew SQ. Measuring quality and impact of telehealth services in home dialysis patients. *Int J Qual Health Care*. 2020;32(3):173-176.



73. Lew SQ, Khan AA, Rieders B, Agrawal ST. Successful use of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) on a pancreatic lesion in a peritoneal dialysis patient without interrupting treatment. *Perit Dial Int.* 2020;40(2):230-232.
74. Lew SQ, Sikka N. Telehealth awareness in a US urban peritoneal dialysis clinic—2018 to 2019. *Perit Dial Int.* 2020;40(2):227-229.
75. Mendu ML, Tummalapalli SL, Lentine KL, Erickson K, Lew SQ, Liu F, Gould E, Somers M, Garimella PS, O’Neil T, White DL, Meyer R, Bieber SD, Weiner DE. Measuring quality in kidney care: an evaluation of existing quality metrics and approach to facilitating improvements in care delivery. *J Am Soc Nephrol* 2020;31(3):602-614.
76. Houghton CC, Lew SQ. Long-term hypervitaminosis D-induced hypercalcaemia treated with glucocorticoids and bisphosphonates. *BMJ Case Rep* 2020 Apr 29;13(4):e233853. Doi:10.1136/bcr-2019-233853
77. Ing TS, Ganta K, Bhave G, Lew SQ, Agaba EI, Argyropoulos C, Tzamaloukas AH. The corrected serum sodium concentration in hyperglycemic crises: computation and clinical applications. *Front Med* 2020;7:477.  
<https://doi.org/10.3389/fmed.2020.00477>
78. Lew, SQ, Wallace EL, Srivatana V, Warady BA, Watnick S, Hood J, White DL, Aggarwal V, Wilkie C, Naljayam M, Gellens M, Perl J, Schreiber MJ. Telehealth for home dialysis in COVID-19 and beyond: a perspective from the American Society of Nephrology COVID-19 Home Dialysis subcommittee. *Am J Kidney Dis.* 2020 doi:<https://doi.org/10.1053/j.ajkd/2020.09.005>
79. Lew SQ, Khan AA, Rieders B, Agrawal ST. Haemoperitoneum after an endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of a pancreatic lesion in a peritoneal dialysis patient. *BMJ Case Rep.* 2020 Nov 4;13(11):e236573. doi: 10.1136/bcr-2020-236573. PMID: 33148597.

b) Papers in Non-Refereed Journals

1. Lew SQ, Bosch JP. Continuous renal replacement: An overview. *Nephrology News & Issues* 1988;2(9):18-20.
2. Cantor ES, Lew S. Hematuria in a middle aged male. *Drug Therapy* 1989;19(8):113-116.
3. Ronco C, Conz P, Bosch JP, Lew SQ, LaGreca G. Assessment of adequacy in peritoneal dialysis. *Adv Ren Replace Ther* 1994;1:15-23.
4. Lew S. How to measure residual kidney function in patients on maintenance hemodialysis. *Adv Ren Replace Ther* 1994;1(2):185-193.
5. Lew SQ. Can low-molecular weight heparin induce thrombocytopenia? *J Critical Illness* 1996;11(12):772-775.
6. Kimmel PL, Lew SQ, Bosch JP. Nutrition, aging and GFR—Is age-associated decline inevitable? *Nephrol Dial Transpl* 1996;11(9):85-88.
7. Lew SQ, Bosch JP. Adequacy of Dialysis. *Kidney: A Current Survey of World Literature* 1997;6:1-4.
8. Lew SQ. Drawbacks of permanent dual lumen central venous silastic catheters for hemodialysis. *Semin Dial* 1996;9(5):402-403.

9. Lew SQ, Kimmel PL. Behavioral compliance in hemodialysis patients. *Contemporary Dialysis and Nephrology* 1998;19(2):30-33.
10. Castillo AA, Lew SQ, Smith AM, Bosch JP. Multidisciplinary case review: Women issues in female patients receiving peritoneal dialysis. *Adv Ren Replace Ther* 1999;6(4):327-334.
11. Lew SQ, Cohn F, Cohen LM, Kimmel PL. Ethical issues in aging and renal disease. *Adv Ren Replace Ther* 1999;7:63-69.
12. Lew SQ, Kaveh K. Dialysis access related infections. *ASAIO J* 2000;46:S6-S12.
13. Lew SQ, Piraino B. Quality of life and psychological issues in peritoneal dialysis patients. *Sem Dial* 2005;18(2):119-123.
14. Lew SQ, Patel SS. Psychosocial and quality of life issues in women with end-stage renal disease. *Adv Chronic Kidney Dis* 2007;14(4):358-363.
15. Moe SM, Crews DC, Gutierrez OM, Hoyt-Hudson P, Lew SQ, Shanaman B, Smith BH, Weiner DE, Wesson D. on behalf of the Rogosin Institute and Center for Health Action and Policy Roundtable on Nutrition Health in Kidney Disease. Food as Medicine: No More Renal “Diet”. *ASN Kidney News* 2016; 8: 16-17.
16. Lew SQ. Maintaining peritoneal dialysis adequacy: The process of incremental prescription. *Adv Perit Dial* 2018;34:10-14.
17. Lew SQ. Telehealth in peritoneal dialysis: Review of patient management. *Adv Perit Dial* 2018;34:32-37.
18. Lew SQ, Collins A. When end-stage kidney disease complicates abdominal surgery. *Semin Dial.* 2020;33(3):270-278

c) Chapters in Books

1. Ronco C, Bosch JP, Lew S, Fecondini L, Fabris A, Feriani M, Chiaramonte S, Brendolan A, Bragantini L, La Greca G. Technical and clinical evaluation of new hemofilter for CAVH: Theoretical concepts and practical application of a different blood flow geometry. In: *Continuous Arteriovenous Hemofiltration*, edited by La Greca G, Fabris A, Ronco C. Milano: Wichtig Editore; 1986. pp. 55-61.
2. Kimmel PL, Phillips TM, Lew SQ, Bosch JP, Langman CB. Zinc and peritoneal macrophage function. In: *Peritoneal Dialysis*, edited by LaGreca G, Ronco C, Feriani M, Chiaramonte S, Conz P. Milano: Wichtig Editore; 1991. pp. 191-195.
3. Lew SQ. Metabolic alkalosis in patients with end stage renal disease. In: *Hemodialysis - High Efficiency Treatments. Contemporary Issues in Nephrology.* edited by Bosch JP, Stein JH. New York, NY: Churchill Livingstone; 1993. pp 263-282.
4. Lew SQ, von Albertini B, Bosch JP. The digestive tract. In: *Handbook of Dialysis.* Daugirdas JT, Blake PG, Ing TS, editors, 3<sup>rd</sup> edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2001. pp 601-610.
5. Kimmel PL, Alam S, Lew SQ. Renal disease in patients who abuse licit and illicit substances. In: McGraw Hill Clinical Medical Series: *Nephrology.* Schena FP, editor, London: McGraw Hill; 2001. pp 237-243.
6. Reyes D, Lew SQ, Kimmel PL. Gender differences in hypertension and kidney disease. In: *Clinics of North America* 2005;89(3):613-630.

7. Lew SQ, Bosch JP. Digestive Tract. In: *Handbook of Dialysis*. Daugirdas JT, Blake PG, Ing TS, editors, 4<sup>th</sup> edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. pp 647-655.
8. Lew SQ, Gruia A. Disinfection of lines and transfer sets in peritoneal dialysis. In: *Disinfection by sodium hypochlorite: Dialysis applications*. Ronco C, Mishkin GJ (editors) Contrib Nephrol. Basel: Karger; 2007. 154: 129-138.
9. Lew SQ, Borum ML, Ing TS. Gastrointestinal complications of acute kidney injury. In: *Management of Acute Kidney Problems*. Jorres A, Ronco C, Kellum JA (editors). Heidelberg, Germany: Springer Publishers; 2010. pp. 209-220.
10. Lew SQ, Bosch JP. Advances in Hemodialysis. In: *Dialysis: History, Development, and Promise*. Todd S. Ing, Mohamed A Rahman, Carl M. Kjellstrand, editors. Singapore: World Scientific; 2012. pp. 793-801.
11. Lew SQ, Radhakrishnan J. Chronic kidney disease and gastrointestinal disorders. In: *Chronic Kidney Disease*. Paul L. Kimmel, Mark Rosenberg, editors. Philadelphia, PA: Elsevier, 2015. pp. 298-309 ISBN: 978-0-12-411602-3.
12. Pham PTT, Pham PCT, Lew SQ. Chronic kidney disease in sickle cell disease patients. In: *Chronic Kidney Disease*. Paul L. Kimmel, Mark Rosenberg, editors. Philadelphia, PA: Elsevier; 2015. pp. 513-52. ISBN: 978-0-12-411602-3.
13. Kurt Lee SM, Tang HL, Sam R, Lew SQ. Steven Chu 1997 Nobel Laureate in Physics. In: *Nobel and Lasker Laureates of Chinese Descent in Literature and Science*. Todd S. Ing, Keith K. Lau, Joseph M. Chan, Hon-Lok Tang, Angela T. Hadsell and Laurence K. Chan, editors. Singapore: World Scientific Publishing Company; 2019. pp.71-84. ISBN: 978-981-4704-60-1.
14. Lew SQ, Kwaan HC, Chan JM, Hadsell AT, Ing TS, Chan LK. Yuet Wai Kan 1991 Albert Lasker Clinical Medical Research Award. In: *Nobel and Lasker Laureates of Chinese Descent in Literature and Science*. Todd S. Ing, Keith K. Lau, Joseph M. Chan, Hon-Lok Tang, Angela T. Hadsell and Laurence K. Chan, editors. Singapore: World Scientific Publishing Company; 2019. pp. 226-242. ISBN: 978-981-4704-60-1.
15. Lew SQ, Radhakrishnan J. Chronic kidney disease and gastrointestinal disorders. In: *Chronic Renal Disease*. Second Edition. Paul L. Kimmel, Mark E. Rosenberg, editors. Elsevier; 2020. pp. 521-539. ISBN: 978-0-12-815876-0.
16. Pham PTT, Pham PCT, Lew SQ. Sickle cell disease. In: *Chronic Renal Disease*. Second Edition. Paul L. Kimmel, Mark E. Rosenberg, editors. Elsevier; 2020. pp. 813-830. ISBN: 978-0-12-815876-0.

d) Books Edited or Written

1. Day-by-Day Dialysis Calendar. Better Living by the Numbers. Masterson T, Lew S, Kaveh K, ed, International Medical Publishing 1999, 2000, 2001, 2002, 2003

e) Abstract

1. Lauer A, Lew S, Glabman S, Bosch JP. Protein loading in diabetic patients: Paradoxical effect on glomerular filtration rate. *Kidney International* 1984;25(1):248. (Presented at the American Society of Nephrology meeting in Washington D.C. 1983.)
2. Bosch JP, Glabman S, Lew S, Lauer A. Diabetic nephropathy: Response to protein loading. *Kidney International* 1985;27(1):241. (Presented at the American Society of Nephrology meeting in Washington D.C. 1984.)
3. Lauer A, Glabman S, Lew S, Bosch JP. Vascular reactivity of the kidney: Assessment by protein loading. *Kidney International* 1985;27(1):245. (Presented at the American Society of Nephrology meeting in Washington D.C. 1984.)
4. Lew S, Bosch JP. Glucose control in diabetes mellitus affects renal vascular response to protein loading. *Kidney International* 1986;29(1):196.
5. Bosch J, Hertel J, Lew S. Renal hemodynamics in diabetics: effect of good and poor metabolic control on protein load. *Kidney International* 1987;31(1):191. (Presented at the American Society of Nephrology meeting in Washington D.C. 1986.)
6. Lew S, Hertel J, Bosch JP. Renal hemodynamics in well controlled diabetics: effect of protein load in captopril and indomethacin treated diabetics. *Kidney International* 1987;31(1):208. (Presented at the American Society of Nephrology meeting in Washington D.C. 1986.)
7. Guerra I, Lew S, Kimmel P, Bosch J. Elevated hematocrit during cyclosporine therapy: Evidence of renal ischemia? Xth International Congress of Nephrology. London, England. 1987
8. Panarello G, Lew S, Bosch J. In vitro hemodynamic evaluation of CAVH. (Presented at the Fifth International Society of Blood Purification. Stockholm, Sweden 1987.)
9. Lew S, Bosch JP. In vitro hemodynamics in CAVH. *Kidney International* 1988;33(1):229. (Presented at the American Society of Nephrology meeting in Washington D.C. 1987.)
10. Bosch JP, Lew S. Protein intake: A major determinant of glomerular filtration rate and creatinine generation in normal man. *Kidney International* 1988;33(1):183. (Presented at the American Society of Nephrology meeting in Washington D.C. 1987.)
11. Ronco C, Bosch JP, Lew S. Studies on blood flow dynamic and ultrafiltration during CAVH. *Kidney International* 1988;33(1):236.
12. Lew S, Habwe V, Bosch JP. Chronic urea loading: Effect on creatinine clearance. (Presented at the Fifth International Congress on Nutrition and Metabolism in Renal Disease in Strasbourg, France 1988.)
13. Habwe V, Lew SQ, Watson J, Earley S, Bosch JP. Effect of hematocrit on solute removal in CAPD. *Kidney International* 1989;35(1):271. (Presented at the American Society of Nephrology meeting in Washington D.C. 1988.)
14. Lew SQ, Drell D, Bosch JP. Albumin excretion rate in normal man: Daily and day to day variation. *Kidney International* 1989;35(1):230. (Presented at the American Society of Nephrology meeting in Washington D.C. 1988.)

15. Lew S, Bosch JP. Diminished creatinine clearance in the elderly: A function of diet or nephron loss? Accepted for presentation at the Fourth Asian Pacific Congress of Nephrology 1989.
16. Lew SQ, Kimmel PL, Li PP, Straw J, Bosch JP. Pharmacokinetics of Zidovudine (AZT) in patients with end stage renal disease (ESRD). *Kidney International* 1990;37(1):307. (Presented at the American Society of Nephrology meeting in Washington D.C. 1989.)
17. Kimmel PL, Lew SQ, Phillips TM, Bosch JP. Low zinc concentration limits peritoneal macrophage interleukin-1 production in CAPD patients. *Kidney International* 1990;37(1):330. (Presented at the American Society of Nephrology meeting in Washington D.C. 1989.)
18. Bosch JP, Lew SQ. The decline in creatinine clearance in the aged: A function of diet or nephron loss? *Kidney International* 1990;37(1):272. (Presented at the American Society of Nephrology meeting in Washington D.C. 1989.)
19. Lew SQ, Kimmel PL, Li PP, Straw J, Loo TL, Bosch JP. Pharmacokinetics of Zidovudine in patients with end stage renal disease. (Presented at the Third Society of Chinese Bioscientists in America, Hong Kong 1990.)
20. Lew SQ, Drell D, Bosch JP. Albumin excretion rate in normal man: Daily and day to day variation. (Presented at the XIth International Congress of Nephrology, Japan 1990.)
21. Lew SQ, Habwe VQ, Watson J, Bosch JP. Effect of hematocrit on solute removal in CAPD. (Presented at the XIth International Congress of Nephrology, Japan 1990.)
22. Lew SQ, Kimmel PL, Li PP, Straw J, Loo TL, Bosch JP. Pharmacokinetics of Zidovudine in patients with end stage renal disease. (Presented at the XIth International Congress of Nephrology, Japan 1990.)
23. Kimmel P, Lew S, Phillips T, Bosch J. Zinc affects mononuclear interleukin-1 production in CAPD patients. (Presented at the XIth International Congress of Nephrology, Japan 1990.)
24. Phillips TM, Kimmel PL, Langman CB, Lew SQ, Bosch JP. Zinc affects peritoneal mononuclear cell calcitriol production in CAPD patients. *J Am Soc Nephrol* 1990;1:588. (Presented at the American Society of Nephrology meeting in Washington D.C. 1990.)
25. Lew SQ, Bosch JP. The effect of protein intake on creatinine clearance in the elderly. *J Am Soc Nephrol* 1990;1:336. (Presented at the American Society of Nephrology meeting in Washington D.C. 1990.)
26. Watson JA, Lew SQ, Habwe VQ, Bosch JP. Is solute removal in CAPD hematocrit dependent? (Presented at the 11<sup>th</sup> Annual Conference on Peritoneal Dialysis, Nashville, TN 1991.)
27. Lew, SQ, Bosch JP. Protein intake in CAPD patients. *J Am Soc Nephrol* 1991;2(3):365. (Presented at the American Society of Nephrology meeting in Washington D.C. 1991.)
28. Wetzel GD, Lew SQ. Phenotypic and functional characterization of lymphoid elements in peritoneal effluent in adult CAPD patients. *J Am Soc Nephrol* 1991;2(3):369. (Presented at the American Society of Nephrology meeting in Washington D.C. 1991.)

29. von Albertini B, Barlee V, Brackett L, Gibson SM, Cappo T, Lew SQ, McCool B, Moore-Price M, Sandoval LE, Parrish AH, Bosch JP. Short high-efficiency dialysis: Clinical outcome. *J Am Soc Nephrol* 1991;2(3):354.
30. von Albertini B, Gibson SM, Lew SQ, Parrish AH, Barlee V, Brackett L, McCool B, Moore-Price M, Sandoval LE, Bosch JP. Short high efficiency dialysis: clinical outcome. XXVIII Congress of the European Renal Association - European Dialysis and Transplant Association.
31. Lew SQ, Watson JA. Urea and creatinine generation and removal in a pregnant patient on peritoneal dialysis. (Presented at the 12<sup>th</sup> Annual conference on Peritoneal Dialysis, Seattle, WA 1992)
32. Sokas RK, Drell D, Simmens S, Lew SQ, Gibson S. Lack of correlation between B2 microglobulinuria and low level lead exposure. (Presented at the American Public Health Association, Washington, D.C.)
33. Abramson F, Pearson P, Lew S, Bosch J. Kinetic analysis of urea compartments in end-stage renal disease patients using stable isotope-labeled urea. (Proceedings of the 40<sup>th</sup> American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics, Washington, DC, June 1992)
34. Bosch JP, Watson J, Ronco C, Lew SQ. Role of total clearance in dietary protein intake in peritoneal dialysis patients. *J Am Soc Nephrol* 1992;3(3):406 (Presented at the American Society of Nephrology, 25<sup>th</sup> Annual Meeting, Baltimore, Maryland)
35. Hertel J, Lew SQ, Barlee V, Bosch JP. Continuous venovenous hemofiltration (CVVH) - the end of continuous arteriovenous hemofiltration/hemodialysis (CAVH/CAVHD). *J Am Soc Nephrol* 1992;3(3):368 (Presented at the American Society of Nephrology Annual Meeting, Baltimore, Maryland)
36. von Albertini B, Bosch J, Brackett L, Gibson S, Lew S, Turner M, Ruley J. Vocational rehabilitation in network aggregate, regional and rates in a high-efficiency unit. *J Am Soc Nephrol* 1992;3(3):401
37. von Albertini B, Bosch J, Gibson S, Lew S, Ruley J, Turner M. Vocational rehabilitation rates in network V, the District of Columbia and a high-efficiency unit. *American Society for Artificial Internal Organs* 1993;90
38. Lew SQ, Pearson P, Abramson F, Bosch JP. Measurement of urea distribution in end stage renal disease patients in a two compartment model. *J Am Soc Nephrol* 1993;4(3):363 (Presented at the American Society of Nephrology Annual Meeting, Boston, MA)
39. Garcia-Valdecasas J, Cerezo S, Bernal MC, Navas-Parejo A, Kimmel P, von Albertini B, Lew SQ, Bosch JP. Epidemiological Factors involved in hepatitis C virus infection in patients with renal diseases. *J Am Soc Nephrol* 1993;4(3):248 (Presented at the American Society of Nephrology Annual Meeting, Boston, MA)
40. von Albertini B, Garcia-Valdecasas J, Barlee V, Lew SQ, Bosch JP. Solute rebound in highly efficient dialysis: Impact on quantification of therapy. *J Am Soc Nephrol* 1993;4(3):393 (Presented at the American Society of Nephrology Annual Meeting, Boston, MA)
41. von Albertini B, Barlee B, Cappo T, Gibson S, Lew S, Siemien R, Bosch J. Vocational rehabilitation in young ESRD patients treated with highly efficient dialysis. *American Society for Artificial Internal Organs* 1994

42. Velasquez MT, von Albertini B, Lew SQ, Moore J, Bosch JP. Shorter treatment time with adequate highly efficient hemodialysis is not associated with higher incidence of hypertension in ESRD patients. *J Am Soc Nephrol* 1994;5(3):532 (Presented at the American Society of Nephrology Annual Meeting, Orlando, FL)
43. Mishkin GJ, Lew SQ, Barlee V, von Albertini B, Bosch JP. In-vitro permanent catheter assessment and evaluation for high efficiency hemodialysis therapy. *J Am Soc Nephrol* 1995;6(3):497 (Presented at the American Society of Nephrology Annual Meeting, San Diego, CA)
44. Osman BA, Lew SQ. Vancomycin removal by plasmapheresis. *Am J Kidney Dis* (Presented at the National Kidney Foundation's Fifth Spring Clinical Nephrology Meeting in Anaheim, CA April 1996)
45. von Albertini B, Mishkin G, Barlee V, Lew SQ, Velasquez M, Bosch JP. Long-term survival outcome with high-efficiency hemodialysis: Effects of treatment time, membrane type and dialyzer reuse. (Presented at the 33<sup>rd</sup> Congress of the EDTA European Renal Association, Amsterdam, The Netherlands June 1996)
46. Lew SQ, Mishkin GJ, von Albertini B, Buenos-Fernandez C, Bosch JP. High blood flow rate does not limit hemodialysis vascular access longevity. *J Am Soc Nephrol* 1996;7:1411 (presented at the American Society of Nephrology Annual Meeting, New Orleans, LA)
47. Velasquez MT, Lew SQ, von Albertini B, Mishkin GJ, Bosch JP. Hypertension control is better during hemodialysis than during continuous ambulatory peritoneal dialysis in ESRD patients. *J Am Soc Nephrol* 1996;7:1468 (presented at the American Society of Nephrology Annual Meeting, New Orleans, LA)
48. Mishkin GJ, von Albertini B, Barlee V, Lew SQ, Vassalotti JA, Velasquez MT, Bosch JP. Specificity and sensitivity of ultrasound dilution for access recirculation measurements. *J Am Soc Nephrol* 1996;7:1414 (presented at the American Society of Nephrology Annual Meeting, New Orleans, LA)
49. von Albertini B, Mishkin G, Lew SQ, Velasquez M, Bosch JP. Long-term survival outcome with high-efficiency dialysis: Effects of time, membrane and reuse. *J Am Soc Nephrol* 1996;7:1468 (presented at the American Society of Nephrology Annual Meeting, New Orleans, LA)
50. Masterson TM, Dickens BF, Lew SQ. Dialysis on the internet: A prototype for renal patient care on the information superhighway. *J Am Soc Nephrol* 1997;8:143A
51. Lew SQ, Gao H, Mishkin GJ, Bosch JP. The impact of body weight and residual renal function on achieving adequate peritoneal dialysis. *J Am Soc Nephrol* 1997;8:286A (Presented at the American Society of Nephrology Annual Meeting, San Antonio, TX)
52. Lew SQ, Gao H, Bosch JP. Correlation analysis between ultrafiltration and diffusive solute clearance by peritoneal equilibration test. *J Am Soc Nephrol* 1997;8:286A (Presented at the American Society of Nephrology Annual Meeting, San Antonio, TX)
53. Velasquez MT, Lew SQ, Mishkin GJ, Zhang Z, Gao H, Bosch JP. Obesity and leptin in hemodialysis patients. *J Am Soc Nephrol* 1997;8:213A (Presented at the American Society of Nephrology Annual Meeting, San Antonio, TX)
54. Castillo AA, Lew SQ, Smith AM, Whyte RL, Mishkin GJ, Varela MP, Bosch JP. Gender differences in calculating total body water explain discrepancies between

- Kt/V and creatinine clearance in peritoneal dialysis patients. *J Am Soc Nephrol* 1998;9:294A (Presented at the American Society of Nephrology Annual Meeting, Philadelphia, PA)
55. Mishkin MA, Mishkin GJ, Barlee V, Lew SQ, Bosch JP. In-vitro assessment of reuse with formaldehyde on the operational characteristics of a new modified cellulose biocompatible hemodialyzer. *J Am Soc Nephrol* 1998;9:178A
  56. Varela P, Mishkin GJ, Castillo A, Lew SQ, Bosch JP. Solute and fluid removal performance in Asahi AM-BIO-1000 Wet dialyzer when reprocessed with renalin. *J Am Soc Nephrol* 1998;9:185A
  57. Varela MP, Kimmel PL, Mishkin GJ, Phillips TM, Lew SQ. Biocompatibility of hemodialysis membranes: Interrelations between plasma complement and cytokine levels. Presented at the XVth International Congress of Nephrology 1999
  58. Lew SQ, Mishkin GJ, Mishkin M, Hill J, Walters BAJ, Bosch JP. Measurement of Kt/V in high efficiency hemodialysis treatments. *J Am Soc Nephrol* 1999;10:333A (Presented at the American Society of Nephrology Annual Meeting, Miami, FL)
  59. Barlee V, Velasquez MT, Mishkin GJ, Mishkin MA, Lew SQ, Vassalotti JA, Bosch JP. Differences in solute clearance between large surface area double high flux and large surface area double high efficiency hemodialysis. *J Am Soc Nephrol* 1999;189A (Presented at the American Society of Nephrology Annual Meeting, Miami, FL)
  60. Barlee V, Vassalotti JA, Velasquez MT, Lew SQ, Mishkin GJ, Bosch JP. Comparison of small and large molecular weight solute clearance with three different methods of hemodiafiltration. *J Am Soc Nephrol* 1999;10:188A (Presented at the American Society of Nephrology Annual Meeting, Miami, FL)
  61. Mishkin GJ, Mishkin M, Barlee V, Lew SQ, Bosch JP. Improved treatment tolerance for patients prone to hypotensive episodes using hemodiafiltration (HDF) with on-line production of substitution fluid. *J Am Soc Nephrol* 1999;10:295A (Presented at the American Society of Nephrology Annual Meeting, Miami, FL)
  62. Kosch DL, Peterson RA, Kimmel PL, Lew SQ. Religion and psychosocial outcomes in urban dialysis patients: Preliminary findings. (The Society of Behavioral Medicine Meeting, Atlanta, GA 2000)
  63. Mishkin MA, Mishkin GJ, Barlee V, Lew SQ, Bosch JP. Peroxyacetic acid reprocessing of the new Asahi APS high flux polysulfone dialyzers does not affect clearance values when reused up to 15 times. *JASN* 2000;11:289A
  64. Barlee V, Lew SQ, Mishkin GJ, Mishkin MA, Bosch JP. Adequate treatment prescription, inadequate treatment delivered: An assessment of treatment variation. *JASN* 2000;11:315A (Presented at the American Society of Nephrology Annual Meeting, Toronto, Canada)
  65. Mishkin GJ, Mishkin MA, Lew SQ, Barlee V, Bosch JP. Membrane permeability (Kp): A classic method to assess new membranes. *JASN* 2000;11:325A
  66. Mishkin MA, Mishkin GJ, Barlee V, Lew SQ. Effects of peroxyacetic acid as a reuse agent on the performance characteristics of high flux polysulfone membranes. *JASN* 2001;12:271A (Presented at the American Society of Nephrology Annual Meeting, San Francisco)
  67. Mishkin MA, Mishkin GJ, Barlee V, Lew SQ, Bosch JP. A novel method for measuring vascular access blood flow on-line without the need for dilution. *JASN*



- 2001;12:297A (Presented at the American Society of Nephrology Annual Meeting, San Francisco)
68. Mishkin GJ, Mishkin MA, Lew SQ, Barlee V, Bosch JP. Maximizing efficiency with double dialyzer hemodialysis: In parallel or in series configuration? JASN 2001;12:271A (Presented at the American Society of Nephrology Annual Meeting, San Francisco)
  69. Mishkin GJ, Mishkin MA, Velasquez MT, Barlee V, Lew SQ. The effects of blood pressure and fluid volume on the measurement of vascular access blood flow. JASN 2001;12:297A (Presented at the American Society of Nephrology Annual Meeting, San Francisco)
  70. Mishkin MA, Mishkin GJ, Lew SQ. Solute removal in hemodiafiltration compared to standard high flux dialysis: Combined analysis of 2 cross over studies. JASN 2002;13:238A (Presented at the American Society of Nephrology Annual Meeting, Philadelphia)
  71. Mishkin GJ, Malan M, Lew SQ, White R, Stephenson Y. Controlling peritonitis rates: Prospective controlled trial of an electrolytic chloroxidizer (Alcavis 50) versus povidone iodine. JASN 2002;13:724A
  72. Mishkin GJ, Gruia A, Mishkin MA, Lew SQ. Improved PD infection rates using electrolytically produced sodium hypochlorite solutions intended for dialysis. JASN 2003;14:221A (Presented at the American Society of Nephrology Annual Meeting, San Diego)
  73. Mishkin MA, Lew SQ. Influence of peroxyacetic acid reprocessing on clearance and Kuf characteristics of a new synthetic low flux dialyzer. JASN 2003;14:819A
  74. Lew SQ: A comparison of second versus third generation parathyroid hormone assays in PD patients. JASN 2004;15:863A
  75. Eustace J, Lew S, Scheel P, Coresh J. Randomized controlled trial of the benefits of oral essential amino acids in hemodialysis patients at high risk for hospitalization. JASN 2006;17: 724A (Presented at the American Society of Nephrology Annual Meeting, San Diego)
  76. Mishkin GJ, Mishkin MA, Lew SQ, Lichy J, Palant CE. Ideal dialyzer combination increases clearance and total ultrafiltration in double dialyzer high flux hemodiafiltration. JASN 2007;18: 250A (Presented at the American Society of Nephrology Annual Meeting, San Francisco)
  77. Lew, SQ. Serum parathyroid hormone level varies with vitamin D dosing schedule in peritoneal dialysis patients. 2011 (Submitted to American Society of Nephrology Annual Meeting, Denver)
  78. Lew SQ, Velasquez MT, Montgomery L, Gerth WA, Montgomery RW. Monitoring intracellular, interstitial and intravascular volume changes during dialysis. 2012 (Presented at the American Society of Nephrology Annual Meeting, San Diego)
  79. Lew SQ, Velasquez MT, Stewart JM, Montgomery LD, Gerth WA, Montgomery RW. Monitoring intravascular, interstitial, & intracellular volume changes during hemodialysis in patients with end-stage renal disease in chronic out-patient & acute in-patient unit settings. 2013 (Presented at the American Society of Nephrology Annual Meeting, Atlanta)

80. Lew SQ, Magnus M, Sikka N. Using daily remote biometric monitoring in peritoneal dialysis. 2015, (Presented at the American Society of Nephrology Annual Meeting, San Diego)
81. Lew SQ, Cheng YL, Ing TS. A novel method of delivering bicarbonate-based dialysis fluid: A 4-stream approach. 2016;94A:SA-OR116. (Oral presentation at the American Society of Nephrology Annual Meeting, Chicago)
82. Lew SQ, Cheng YL, Ing TS. A novel method of widening the range of dialysis fluid sodium concentration using a 4-stream approach. 2016;316A:TH-PO955 (Presented at the American Society of Nephrology Annual Meeting, Chicago)
83. Emami S, Lew S. Candida glabrata fungal peritonitis in continuous ambulatory peritoneal dialysis patients, a case report. 2017 (Presented at the American Society of Nephrology Annual Meeting, New Orleans)
84. Lew SQ, Sikka N. Operationalizing telemedicine for home dialysis patients. 2018 (American Society of Nephrology Annual Meeting, San Diego)
85. Lew SQ, Khan AA, Rieders B, Agrawal ST. Using endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) on pancreatic lesions in peritoneal dialysis (PD) patients. 2019 (Presented at the American Society of Nephrology Annual Meeting, Washington, DC)

## 11) Presentations:

### a) Regional

- Jan. 1986 "Diabetic nephropathy", Seminar on Current Research,  
George Washington University Medical Center, Washington, D.C.
- Sept. 1986 "Causes and prevention of diabetic nephropathy",  
Washington Hospital Center, Washington, D.C.
- Nov. 1986 "Benefits of exercise",  
National Kidney Foundation Patient/Family Seminar,  
Greater Southeast Community Hospital, Washington, D.C.
- April 1987 "Benefits of exercise",  
National Kidney Foundation Patient/Family Seminar,  
Fairfax Hospital, Fairfax, VA
- Jan. 1988 "The effect of a vegetarian diet on kidney function",  
Vegetarian Society of D.C., Washington, D.C.
- July 1988 "Protein: Can you get too much of a good thing?",  
George Washington University Medical Center, Washington, D.C.
- May 1989 "Protein: How much?", "Lifestyles to Health", WGTS 91.9 FM,  
Capital Health Center, Takoma Park, MD
- Sept 1991 "Renal Case Studies", Primary Care Update and Board Review,  
Washington, DC
- June 1992 "Factors that play a role in glomerular filtration rate",  
Doctor's Hospital Prince George, MD
- Sept 1992 "Renal Case Studies",  
Primary Care Update and Board Review, Washington, DC
- April 1993 "Treatment of Infections in ESRD Patients",  
Basic Dialysis for Renal Fellows and Practicing Nephrologists,  
Washington, DC
- Sept 1995 "40 year old woman who presents with delirium and elevated lithium  
level", Medicine Grand Round - case of the month,  
George Washington University Medical Center, Washington, DC
- Dec 1997 "Adequacy in Peritoneal Dialysis",  
Washington Hospital Center, Washington, DC
- Jan 1999 Renal Disorders/Hemodialysis in Elderly,  
Geriatrics Grand Rounds Conferences,  
George Washington University Hospital, Washington, DC
- Apr 1999 "CRRT: Different Techniques for Different Problems",  
National Kidney Foundation, (Two-Day Course on Hemodialysis),  
Washington, DC
- May 1999 "Urinalysis", Workup and Evaluation of Kidney Disease:  
Insights gained from Urinalysis and Radiographic Techniques",  
Nephrology for the Primary Care Physician,  
National Kidney Foundation, Washington, DC
- Jan 2000 "Diabetic Nephropathy", Medical Answers, Fairfax, VA
- Feb 2000 "Pre-dialysis", Medical Answers, Fairfax, VA
- April 2001 "Intense Blood Pressure Control", Novartis, Washington, DC
- Dec 2001 "Management of anemia with Aranesp", Amgen, McLean, VA

- May 2002 “Angiotension Receptor Blockers: Theoretical and Practical Issues in Combination Therapy for Hypertension Management”, AstraZeneca, Washington, DC
- Oct 2002 “Hypertension”, George Washington University Community Health Expo, Washington, DC
- Jan 2003 “Dialysis Clearance Update”, Johns Hopkins Bayview Medical Center, Baltimore, MD
- Mar 2003 “Hypertension in the elderly”, George Washington University, Washington, DC
- Mar 2003 “Hypertension-Silent Killer of Women”, MFA Women’s Health Congress, Washington, DC
- Sept 2003 “Optimizing the synergy between physicians and nurses to improve care in anemia in PD patients”, Gambro West PD Summit, Las Vegas, NV
- Apr 2004 “Simplifying anemia management in CKD”, Amgen, Washington, DC
- Jun 2004 “New treatments for comorbidities of chronic renal disease”, Amgen, Washington, DC
- Oct 2004 “Anemia Therapy”, Ortho Biotech Products, Washington, DC
- Oct 2004 “Treatments for co-morbidities of chronic kidney disease”, Providence Hospital, Washington, DC
- Apr 2005 “Update on End Stage Renal Disease”, FDA, Rockville, MD
- Jun 2005 “BEACTIVE”, Ortho Biotech Products, Washington, DC
- Jul 2005 “BEACTIVE”, Ortho Biotech Products, McLean, VA
- Aug 2005 “BEACTIVE”, Ortho Biotech Products, Washington, DC
- Sept 2005 “CKD and anemia: Cardiovascular double jeopardy”, Amgen, Washington, DC
- Sept 2005 “Managing CKD anemia”, Amgen, Annapolis, MD
- Oct 2005 “ABCs of CKD”, Amgen, Washington, DC
- Nov 2005 “Changes in peritoneal dialysis technology”, Johns Hopkins Bayview Medical Center, Baltimore, MD
- Dec 2005 “Strategies for early intervention in the disease continuum: Diabetes, CKD, Secondary hyperparathyroidism”, Vienna, VA
- Mar 2006 “New options in diagnosis and treatment of secondary hyperparathyroidism in chronic kidney disease stage 3 and 4”, Sibley Hospital Grand Rounds, Washington, DC
- Apr 2006 “Managing chronic kidney disease anemia”, Columbia, MD
- May 2006 “Treatment of anemia and chronic kidney disease”, Washington County Hospital Grand Rounds, Hagerstown, MD
- June 2006 “Polycystic kidney Disease”, Providence Hospital, Washington, DC
- Sept 2006 “Cardiovascular complications associated with ESRD” DaVita , Alexandria, VA
- Oct 2006 “Examining the link between chronic kidney disease and vascular calcification for patients on dialysis”, Abbott, Bethesda, MD
- Oct 2006 “Managing anemia in kidney disease patients”, Ortho Biotech, Alexandria, VA

- Nov 2006 "Peritoneal Dialysis", George Washington University Medical Center, Washington, DC
- Mar 2007 "Hematuria" Providence Hospital, Washington, DC
- Oct 2007 "Sensipar and improved management of secondary hyperparathyroidism in dialysis patients" Amgen, Vienna, VA
- Oct 2007 "EPOGEN dynamic anemia management" Amgen, Germantown, VA
- Nov 2007 "Update on the use of continuous renal replacement in the ICU" Medical Grand Rounds, George Washington University, Washington, DC
- May 2008 "A chronic kidney disease (CKD) disease awareness initiative" Ortho Biotech, Washington, DC
- Aug 2008 "Why not Peritoneal Dialysis?", FMC, Milford, DE
- Oct 2008 "Peritoneal Dialysis", The Nation's Capital Home Dialysis Review, DaVita, Washington, DC
- Oct 2008 "Chronic Dialysis", Providence Hospital, Washington, DC
- Nov 2008 "Non-infectious complications of peritoneal dialysis", The Nation's Capital Home Dialysis Review, DaVita, Washington, DC
- Mar 2009 "Kidney Failure; Epidemiology and ethical issues", School of Public Health, George Washington University, Washington, DC
- June 2009 "Acute renal failure", Providence Hospital, Washington, DC
- Sept 2009 "Vitamin D: Improving outcomes in CKD", Genzyme, Washington, DC
- Sept 2009 "Peritoneal dialysis for fellows" DaVita, Washington, DC
- Dec 2009 "What's new in dialysis" George Washington University Medicine Grand Rounds, Washington, DC
- Dec 2010 "Nephrotic Syndrome", Providence Hospital, Washington, DC
- Mar 2012 "Chronic dialysis", Providence Hospital, Washington, DC
- Jun 2012 "The role of technology and innovation in peritoneal dialysis", George Washington University Medical Grand Rounds, Washington, DC
- Mar 2013 "Peritoneal Dialysis for the Housestaff", George Washington University Medical Center, Washington, DC
- Mar 2015 "Peritoneal Dialysis: Innovation to Initiation", George Washington University Medicine Grand Rounds, Washington, DC
- Feb 2017 "Chronic kidney disease and continuous renal replacement therapy", Providence Hospital, Washington, DC
- Oct 2017 "Chronic kidney disease and continuous renal replacement therapy", Providence Hospital, Washington, DC
- Apr 2018 "Nephrology-Related Emergencies", Department of Emergency Medicine, George Washington University, Washington, DC
- Apr 2018 "Peritoneal Dialysis", Department of Medicine George Washington University, Washington, DC
- Apr 2018 "Chronic kidney disease", Department of Medicine George Washington University, Washington, DC
- Mar 2019 "Nephrologist's approach to patients with diabetes mellitus", Project Extension for Community Healthcare Outcomes (ECHO) George Washington University, Washington, DC
- Jan 2020 "Hypertension: Beyond the ACEI and ARB in diabetes", Project Extension for Community Healthcare Outcomes (ECHO)

George Washington University, Washington, DC

- b) National
- April 1985 “Continuous arterio-venous hemofiltration”,  
Mount Carmel Mercy Hospital, Detroit, MI
- Sept. 1985 “Practical aspects of hemofiltration”, Continuous Arterial Venous  
Hemofiltration: Update,  
George Washington University, Annapolis, MD
- Nov. 1985 “Ultrafiltration”, Seventh Annual Scientific Symposium,  
New Jersey Society Critical Care Medicine, Jamesburg, NJ
- April 1990 “Effect of blood compartments on solute transport: Donnan equilibrium”  
American Society for Artificial Internal Organs, Washington, D.C.
- April 1991 “Gastrointestinal hemorrhage in ESRD patients”,  
American Society for Artificial Internal Organs, Chicago, IL
- May 1992 “Continuous venovenous hemofiltration (CVVH)”,  
American Society for Artificial Internal Organs, Nashville, TN
- April 1996 “Continuous veno-venous hemofiltration”,  
National Kidney Foundation’s  
Fifth Annual Spring Clinical Nephrology Meetings, Anaheim, CA
- May 1996 “Continuous veno-venous hemofiltration”,  
American Society for Artificial Internal Organs,  
42<sup>nd</sup> Annual Conference- Vanguard in Dialysis, Washington, DC
- Nov 1996 “Measuring the delivered peritoneal dialysis”,  
Invited Mini Lecture  
American Society of Nephrology: 29<sup>th</sup> Annual Meeting, New Orleans, LA
- June 1998 “Vascular complications: Aneurysms and high blood pressure,  
9<sup>th</sup> Annual Conference on Polycystic Kidney Disease,  
Polycystic Kidney Disease Research Foundation, Arlington, VA
- Nov 2006 “Using Sensipar to improve the management of secondary  
hyperparathyroidism in patients on dialysis”  
Amgen, Goldsboro, NC
- Apr 2007 “Using Sensipar to improve the management of secondary  
hyperparathyroidism in patients on dialysis” Amgen, Columbia, SC
- Sept 2007 “Complications of CKD”, NKF of Southern California, Palms Spring, CA
- Nov 2008 “Physiology and kinetics of the peritoneum: The peritoneum as a  
dialyzer”, Advanced Renal Education Program, Fresenius Medical Care,  
West Conshohocken, PA
- Nov 2008 “Peritoneal dialysis prescription”, Advanced Renal Education Program,  
Fresenius Medical Care, West Conshohocken, PA
- Apr 2009 “Physiology and kinetics of the peritoneum: The peritoneum as a  
dialyzer”, Advanced Renal Education Program, Fresenius Medical Care,  
Atlanta, GA
- Apr 2009 “Peritoneal dialysis prescription”, Advanced Renal Education Program,  
Fresenius Medical Care, Atlanta, GA
- May 2009 “Physiology and kinetics of the peritoneum: The peritoneum as a  
dialyzer”,

- May 2009 Advanced Renal Education Program, Fresenius Medical Care, Newark, NJ  
“Peritoneal dialysis prescription”, Advanced Renal Education Program,  
Fresenius Medical Care, Newark, NJ
- May 2009 “Dynamic anemia management”, Amgen, Baltimore, MD
- May 2009 “Sensipar and improved management of secondary hyperparathyroidism”,  
Amgen, Baltimore, MD
- Oct 2009 “Improving quality of care in the first year of dialysis” Amgen, Tampa, FL
- Oct 2009 “BEACTIVE in long-term care”, Ortho Biotech, Hunt Valley, MD
- Nov 2009 “The risks and consequences of abnormal mineral metabolism in  
secondary hyperparathyroidism”, Amgen,  
Clearwater, Ocala, & Jacksonville, FL
- Nov 2009 “Diagnosis, evaluation and management of chronic renal failure”  
Urology Nursing Society, Inc, Arlington, VA
- Mar 2010 “Physiology and kinetics of the peritoneum: The peritoneum as a  
dialyzer”,  
Advanced Renal Education Program, Fresenius Medical Care, Kansas  
City, MO
- May 2009 “Peritoneal dialysis prescription”, Advanced Renal Education Program,  
Fresenius Medical Care, Kansas City, MO
- May 2010 “Improving quality of care in the first year of dialysis”  
Amgen, Merrillville, IN and West Orland Park, IL
- May 2010 “Physiology and kinetics of the peritoneum: The peritoneum as a  
dialyzer”,  
Advanced Renal Education Program, Fresenius Medical Care,  
Charlottesville, VA
- May 2010 “Peritoneal dialysis prescription”, Advanced Renal Education Program,  
Fresenius Medical Care, Charlottesville, VA
- May 2010 “Medical director’s role in vascular access”,  
MARC Spring Council Meeting, Fredericksburg, VA
- Sept 2010 “Optimizing Quality Outcomes in the Bundle”, Amgen, Coral Gables, FL
- Mar 2011 “Challenges in peritoneal dialysis”, Johns Hopkins, Baltimore, MD
- Aug 2011 “Tradjenta: A new DPP-4 inhibitor for the treatment of adult patients with  
Type 2 diabetes mellitus”, Boehringer Ingelheim, Salisbury, MD
- May 2013 “Peritoneal Dialysis: The role of technology and innovation—past,  
present, future”,  
Renal Grand Rounds at Drexel University/Hahnemann Hospital,  
Philadelphia, PA
- July 2015 “Home Therapies”, Renal Physicians Association, 2015 Advanced  
Practitioner Conference, Annapolis, MD
- May 2016 ‘Clinical trials in nephrology: Tools to tackle recruitment and retention’,  
panelist. Kidney Health Initiative, American Society of Nephrology,  
Silver Springs, MD
- Nov 2016 ‘Home dialysis and the future of remote patient monitoring in  
nephrology’, iPatient: Providing kidney care via telehealth at the  
American Society of Nephrology 2016 Kidney Week, Chicago, IL

- Mar 2018 ‘Telehealth in peritoneal dialysis patient management’, Annual Dialysis Conference, University of Missouri Division of Nephrology, Orlando, FL
- Mar 2018 ‘Maintaining PD adequacy: The process of incremental prescription’, Annual Dialysis Conference, University of Missouri Division of Nephrology, Orlando, FL
- Mar 2019 “Role of telehealth to manage PD catheter problems” Annual Dialysis Conference, University of Missouri Division of Nephrology, Dallas, Tx
- Mar 2019 “Measuring quality and impact of telehealth services” Annual Dialysis Conference, University of Missouri Division of Nephrology, Dallas, Tx
- Apr 2020 “Telehealth experience during COVID-19” COVID-19 Home Physician Call, Davita Kidney Care
- Jun 2020 “ASN Roundtable: Telehealth for kidney care, beyond COVID-19” American Society of Nephrology Webinar
- Oct 2020 “Telemedicine and home dialysis: virtual care real opportunities” American Society of Nephrology 2020 Kidney Week, Virtual
- Nov 2020 “How to get the most out of your telehealth visit” RSN’s 27<sup>th</sup> Annual Patient Education Meeting. Renal Support Network’s Hope Week (Nov 10-14, 2020), Virtual

c) International

- May 1991 “Effect of protein intake on creatinine clearance”, Nephrology Seminars Medicine & Surgery, University of Modena, Modena, Italy

**12) Services to Community**

a) International

1. Moderator for: “Back to the future: home, wearable, implantable therapies” Inaugural Global Summit on Innovations in Patient-Centered Kidney Care, May 21-23, 2019; AAKP & GWU; Washington, DC

b) National

1. Moderator for: 1997 American Society of Nephrology Clinical Symposium: “High Blood Pressure in ESRD: Causes and Consequences” San Antonio, TX
2. Co-chair for: 1998 American Society of Nephrology Plenary Session: “Complications of Peritoneal Dialysis”, Philadelphia, PA
3. Abstract reviewer: 2006 American Society Nephrology Category: Dialysis: Epidemiology, Health Services Research, and Ethics
4. Co-Chair: 2007 ASN Renal Weekends, Washington, DC
5. Board member: 2007-2010: American Nephrology Council
6. Board member: 2010-2011: American Kidney Fund
7. Kidney Health Initiative member: 2016--
8. Steering committee member: Connected Health Initiative 2016—
9. American Society of Nephrology: Quality Committee (1/1)2019-(12/31)2020



10. Renal Physician Association (RPA) Expert Online Panelist: “Utilizing Telehealth to Manage Patients Receiving Dialysis Care,” June 15-August 1, 2019
11. Co- Moderator for: 2019 American Society of Nephrology Oral presentation: “Peritoneal Dialysis: Innovations and Clinical Practice,” Washington, DC

c) Regional

- |             |  |
|-------------|--|
| 1988 – 1992 | Chinese Medical & Health Association Health Fair   |
| 2002-2003   | Washington, DC Nephrology Interest Group<br>American Society of Nephrology / Women in Nephrology |
| 2011 Nov    | National Kidney Foundation (KEEP) program (Centerville, VA)                                      |
| 2012 Jan    | National Kidney Foundation ‘News 4 Your Health Fair’--DC   |
| 2012 Mar    | National Kidney Foundation (KEEP) program (DC)   |
| 2012 Apr    | National Kidney Foundation (KEEP) program (Vienna, VA)   |
| 2012 Sept   | American Kidney Fund: Kidney Action Day—DC   |
| 2013 Mar    | National Kidney Foundation ‘News 4 Your Health Fair’—DC  |
| 2013 May    | National Kidney Foundation (KEEP) program (Vienna, VA)   |
| 2014 Jan    | National Kidney Foundation ‘News 4 Your Health Fair’—DC  |
| 2014-2018   | Network 5 Medical Review Board member<br>Mid-Atlantic Renal Coalition                            |
| 2015        | American College of Physician Mentoring Program  |
| 2019-2021   | Network 5 (Quality Insights) Board of Directors  |